1 6456 130 THYMOSIN BETA4 PREVENTS OXIDATIVE STRESS, INFLAMMATION, AND FIBROSIS IN ETHANOL- AND LPS-INDUCED LIVER INJURY IN MICE. THYMOSIN BETA 4 (TBETA4), AN ACTIN-SEQUESTERING PROTEIN, IS INVOLVED IN TISSUE DEVELOPMENT AND REGENERATION. IT PREVENTS INFLAMMATION AND FIBROSIS IN SEVERAL TISSUES. WE INVESTIGATED THE ROLE OF TBETA4 IN CHRONIC ETHANOL- AND ACUTE LIPOPOLYSACCHARIDE- (LPS-) INDUCED MOUSE LIVER INJURY. C57BL/6 MICE WERE FED 5% ETHANOL IN LIQUID DIET FOR 4 WEEKS PLUS BINGE ETHANOL (5 G/KG, GAVAGE) WITH OR WITHOUT LPS (2 MG/KG, INTRAPERITONEAL) FOR 6 HOURS. TBETA4 (1 MG/KG, INTRAPERITONEAL) WAS ADMINISTERED FOR 1 WEEK. WE DEMONSTRATED THAT TBETA4 PREVENTED ETHANOL- AND LPS-MEDIATED INCREASE IN LIVER INJURY MARKERS AS WELL AS CHANGES IN LIVER PATHOLOGY. IT ALSO PREVENTED ETHANOL- AND LPS-MEDIATED INCREASE IN OXIDATIVE STRESS BY DECREASING ROS AND LIPID PEROXIDATION AND INCREASING THE ANTIOXIDANTS, REDUCED GLUTATHIONE AND MANGANESE-DEPENDENT SUPEROXIDE DISMUTASE. IT ALSO PREVENTED THE ACTIVATION OF NUCLEAR FACTOR KAPPA B BY BLOCKING THE PHOSPHORYLATION OF THE INHIBITORY PROTEIN, IKAPPAB, THEREBY PREVENTED PROINFLAMMATORY CYTOKINE PRODUCTION. MOREOVER, TBETA4 PREVENTED FIBROGENESIS BY SUPPRESSING THE EPIGENETIC REPRESSOR, METHYL-CPG-BINDING PROTEIN 2, THAT COORDINATELY REVERSED THE EXPRESSION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA AND DOWNREGULATED FIBROGENIC GENES, PLATELET-DERIVED GROWTH FACTOR-BETA RECEPTOR, ALPHA-SMOOTH MUSCLE ACTIN, COLLAGEN 1, AND FIBRONECTIN, RESULTING IN REDUCED FIBROSIS. OUR DATA SUGGEST THAT TBETA4 HAS ANTIOXIDANT, ANTI-INFLAMMATORY, AND ANTIFIBROTIC POTENTIAL DURING ALCOHOLIC LIVER INJURY. 2018 2 4747 40 NOVEL MODULATORS OF HEPATOSTEATOSIS, INFLAMMATION AND FIBROGENESIS. ALCOHOLIC STEATOSIS, INSTEAD OF BEING INNOCUOUS, PLAYS A CRITICAL ROLE IN LIVER INFLAMMATION AND FIBROGENESIS. THE SEVERITY OF FATTY LIVER IS GOVERNED BY THE CONCERTED BALANCE BETWEEN LIPID TRANSPORT, SYNTHESIS, AND DEGRADATION. WHEREAS SCAVENGER RECEPTOR CLASS B, TYPE I (SR-B1) IS CRITICAL FOR REVERSE CHOLESTEROL UPTAKE BY THE LIVER, PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA (PPARGAMMA) COACTIVATOR-1ALPHA AND -BETA (PGC1ALPHA AND PGC1BETA) ARE CRITICAL FOR LIPID DEGRADATION AND SYNTHESIS, RESPECTIVELY. BECAUSE BETAINE IS A LIPOTROPIC AGENT, WE HAVE EVALUATED ITS EFFECTS ON ALCOHOLIC STEATOSIS. BETAINE EFFECTIVELY PREVENTED CHRONIC ALCOHOL-MEDIATED (I) IMPAIRED SR-B1 GLYCOSYLATION, PLASMA MEMBRANE LOCALIZATION, AND CONSEQUENT IMPAIRED CHOLESTEROL TRANSPORT; AND (II) UP REGULATION OF PGC-1BETA, STEROL REGULATORY ELEMENT-BINDING PROTEIN 1C AND DOWNSTREAM LIPOGENIC GENES WITH CONCOMITANT INCREASED LIVER CHOLESTEROL, TRIGLYCERIDES AND HEPATIC LIPID SCORE. SIMILARLY, BECAUSE OF ITS ANTI-INFLAMMATORY AND ANTI-FIBROTIC EFFECTS IN OTHER ORGANS, WE EVALUATED THE PROTECTIVE EFFECTS OF THYMOSIN BETA4 (TBETA4) AGAINST CARBON TETRACHLORIDE (CCL4)-INDUCED HEPATOTOXICITY IN RAT. TBETA4 PREVENTED CCL4-INDUCED (I) NECROSIS, INFLAMMATORY INFILTRATION AND UP-REGULATION OF ALPHA1(2)COLLAGEN, ALPHA-SMOOTH MUSCLE ACTIN (ALPHA-SMA), PLATELET DERIVED GROWTH FACTOR BETA (PDGF-BETA) RECEPTOR AND FIBRONECTIN MRNA EXPRESSION; (II) DOWN-REGULATION OF ADIPOGENIC GENE, PPARGAMMA AND THE UP-REGULATION OF EPIGENETIC REPRESSOR GENE, METHYL CPG BINDING PROTEIN 2 (MECP2) MRNA LEVELS, SUGGESTING THAT THE ANTI-FIBROGENIC ACTIONS OF TBETA4 INVOLVE THE PREVENTION OF TRANS-DIFFERENTIATION OF QUIESCENT HEPATIC STELLATE CELLS INTO MYO-FIBROBLASTS LARGELY BY UP-REGULATING PPARGAMMA AND BY DOWN-REGULATING MECP2 GENES. WE THEREFORE CONCLUDE THAT BETAINE AND TBETA4 CAN EFFECTIVELY PROTECT AGAINST ALCOHOLIC HEPATOSTEATOSIS AND HEPATIC FIBROGENESIS, RESPECTIVELY. 2014 3 894 35 CHRONIC ETHANOL FEEDING ALTERS HEPATOCYTE MEMORY WHICH IS NOT ALTERED BY ACUTE FEEDING. BACKGROUND: GENE EXPRESSION CHANGES IN THE LIVER AFTER ACUTE BINGE DRINKING MAY DIFFER FROM THE CHANGES SEEN IN CHRONIC ETHANOL FEEDING IN THE RAT. THE CHANGES IN GENE EXPRESSION AFTER CHRONIC ETHANOL FEEDING MAY SENSITIZE THE LIVER TO ALCOHOL-INDUCED LIVER DAMAGE, WHICH IS NOT SEEN AFTER ACUTE BINGE DRINKING. METHODS: TO TEST THIS HYPOTHESIS, GENE MICROARRAY ANALYSIS WAS PERFORMED ON THE LIVERS OF RATS (N = 3) FED AN ACUTE BINGE DOSE OF ETHANOL (6 G/KG BODY WT) AND KILLED AT 3 AND 12 HOURS AFTER ETHANOL BY GAVAGE. THE GENE MICROARRAYS WERE COMPARED WITH THOSE MADE ON THE LIVER OF RATS FROM A PREVIOUS STUDY, IN WHICH THE RATS WERE FED ETHANOL BY INTRAGASTRIC TUBE FOR 1 MONTH (36% OF CALORIES DERIVED FROM ETHANOL). RESULTS: MICROARRAY ANALYSIS DATA VARIED BETWEEN THE ACUTE AND CHRONIC MODELS IN SEVERAL IMPORTANT RESPECTS. GROWTH FACTORS INCREASED MAINLY IN THE CHRONIC ALCOHOL FED RAT. CHANGES IN ENZYMES INVOLVED IN OXIDATIVE STRESS WERE NOTED ONLY WITH CHRONIC ETHANOL FEEDING. GENE EXPRESSION OF FAT METABOLISM WAS INCREASED ONLY WITH CHRONIC ETHANOL FEEDING. MOST IMPORTANTLY, EPIGENETIC RELATED ENZYMES AND ACETYLATION AND METHYLATION OF HISTONES CHANGED ONLY AFTER CHRONIC ETHANOL FEEDING. CONCLUSIONS: THE RESULTS SUPPORT THE CONCEPT THAT CHRONIC ETHANOL INGESTION INDUCES ALTERED GENE EXPRESSION AS A RESULT OF CHANGES IN EPIGENETIC MECHANISMS, WHERE ACETYLATION AND METHYLATION OF HISTONES WERE ALTERED. 2009 4 2780 29 EZH2 DOWN-REGULATION EXACERBATES LIPID ACCUMULATION AND INFLAMMATION IN IN VITRO AND IN VIVO NAFLD. NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS ONE OF THE MOST PREVALENT, CHRONIC LIVER DISEASES, WORLDWIDE. IT IS A MULTIFACTORIAL DISEASE CAUSED BY COMPLEX INTERACTIONS BETWEEN GENETIC, EPIGENETIC AND ENVIRONMENTAL FACTORS. RECENTLY, SEVERAL MICRORNAS, SOME OF WHICH EPIGENETICALLY REGULATED, HAVE BEEN FOUND TO BE UP- AND/OR DOWN-REGULATED DURING NAFLD DEVELOPMENT. HOWEVER, IN NAFLD, THE ESSENTIAL ROLE OF THE POLYCOMB GROUP PROTEIN ENHANCER OF ZESTE HOMOLOG 2 (EZH2), WHICH CONTROLS THE EPIGENETIC SILENCING OF SPECIFIC GENES AND/OR MICRORNAS BY TRIMETHYLATING LYS27 ON HISTONE H3, STILL REMAINS UNKNOWN. IN THIS STUDY, WE DEMONSTRATE THAT THE NUCLEAR EXPRESSION/ACTIVITY OF THE EZH2 PROTEIN IS DOWN-REGULATED BOTH IN LIVERS FROM NAFLD RATS AND IN THE FREE FATTY ACID-TREATED HEPG2. THE DROP IN EZH2 IS INVERSELY CORRELATED WITH: (I) LIPID ACCUMULATION; (II) THE EXPRESSION OF PRO-INFLAMMATORY MARKERS INCLUDING TNF-ALPHA AND TGF-BETA; AND (III) THE EXPRESSION OF MIR-200B AND MIR-155. CONSISTENTLY, THE PHARMACOLOGICAL INHIBITION OF EZH2 BY 3-DEAZANEPLANOCIN A (DZNEP) SIGNIFICANTLY REDUCES EZH2 EXPRESSION/ACTIVITY, WHILE IT INCREASES LIPID ACCUMULATION, INFLAMMATORY MOLECULES AND MICRORNAS. IN CONCLUSION, THE RESULTS OF THIS STUDY SUGGEST THAT THE DEFECTIVE ACTIVITY OF EZH2 CAN ENHANCE THE NAFLD DEVELOPMENT BY FAVOURING STEATOSIS AND THE DE-REPRESSION OF THE INFLAMMATORY GENES AND THAT OF SPECIFIC MICRORNAS. 2013 5 613 33 BINGE ALCOHOL ALTERS PNPLA3 LEVELS IN LIVER THROUGH EPIGENETIC MECHANISM INVOLVING HISTONE H3 ACETYLATION. THE HUMAN PNPLA3 (PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING 3) GENE CODES FOR A PROTEIN WHICH IS HIGHLY EXPRESSED IN ADIPOSE TISSUE AND LIVER, AND IS IMPLICATED IN LIPID HOMEOSTASIS. WHILE PNPLA3 PROTEIN CONTAINS REGIONS HOMOLOGOUS TO FUNCTIONAL LIPOLYTIC PROTEINS, THE REGULATION OF ITS TISSUE EXPRESSION IS REFLECTIVE OF LIPOGENIC GENES. A NATURALLY OCCURRING GENETIC VARIANT OF PNPLA3 IN HUMANS HAS BEEN LINKED TO INCREASED SUSCEPTIBILITY TO ALCOHOLIC LIVER DISEASE. WE HAVE EXAMINED THE MODULATORY EFFECT OF ALCOHOL ON PNPLA3 PROTEIN AND MRNA EXPRESSION AS WELL AS THE ASSOCIATION OF ITS GENE PROMOTER WITH ACETYLATED HISTONE H3K9 BY CHROMATIN IMMUNOPRECIPITATION (CHIP) ASSAY IN RAT HEPATOCYTES IN VITRO, AND IN VIVO IN MOUSE AND RAT MODELS OF ACUTE BINGE, CHRONIC, AND CHRONIC FOLLOWED BY ACUTE BINGE ETHANOL ADMINISTRATION. PROTEIN EXPRESSION OF PNPLA3 WAS SIGNIFICANTLY INCREASED BY ALCOHOL IN ALL THREE MODELS USED. PNPLA3 MRNA ALSO INCREASED, ALBEIT TO A VARYING DEGREE. CHIP ASSAY USING H3ACK9 ANTIBODY SHOWED INCREASED ASSOCIATION WITH THE PROMOTER OF PNPLA3 IN HEPATOCYTES AND IN MOUSE LIVER. THIS WAS LESS EVIDENT IN RAT LIVERS IN VIVO EXCEPT UNDER CHRONIC TREATMENT. IT IS CONCLUDED FOR THE FIRST TIME THAT HISTONE ACETYLATION PLAYS A ROLE IN THE MODULATION OF PNPLA3 LEVELS IN THE LIVER EXPOSED TO BINGE ETHANOL BOTH IN VITRO AND IN VIVO. 2017 6 2590 32 EPIGENETICS OF PROTEASOME INHIBITION IN THE LIVER OF RATS FED ETHANOL CHRONICALLY. AIM: TO EXAMINE THE EFFECTS OF ETHANOL-INDUCED PROTEASOME INHIBITION, AND THE EFFECTS OF PROTEASOME INHIBITION IN THE REGULATION OF EPIGENETIC MECHANISMS. METHODS: RATS WERE FED ETHANOL FOR 1 MO USING THE TSUKAMOTO-FRENCH MODEL AND WERE COMPARED TO RATS GIVEN THE PROTEASOME INHIBITOR PS-341 (BORTEZOMIB, VELCADE(TM)) BY INTRAPERITONEAL INJECTION. MICROARRAY ANALYSIS AND REAL TIME PCR WERE PERFORMED AND PROTEASOME ACTIVITY ASSAYS AND WESTERN BLOT ANALYSIS WERE PERFORMED USING ISOLATED NUCLEI. RESULTS: CHRONIC ETHANOL FEEDING CAUSED A SIGNIFICANT INHIBITION OF THE UBIQUITIN PROTEASOME PATHWAY IN THE NUCLEUS, WHICH LED TO CHANGES IN THE TURNOVER OF TRANSCRIPTIONAL FACTORS, HISTONE-MODIFYING ENZYMES, AND, THEREFORE, AFFECTED EPIGENETIC MECHANISMS. CHRONIC ETHANOL FEEDING WAS RELATED TO AN INCREASE IN HISTONE ACETYLATION, AND IT IS HYPOTHESIZED THAT THE PROTEASOME PROTEOLYTIC ACTIVITY REGULATED HISTONE MODIFICATIONS BY CONTROLLING THE STABILITY OF HISTONE MODIFYING ENZYMES, AND, THEREFORE, REGULATED THE CHROMATIN STRUCTURE, ALLOWING EASY ACCESS TO CHROMATIN BY RNA POLYMERASE, AND, THUS, PROPER GENE EXPRESSION. PROTEASOME INHIBITION BY PS-341 INCREASED HISTONE ACETYLATION SIMILAR TO CHRONIC ETHANOL FEEDING. IN ADDITION, PROTEASOME INHIBITION CAUSED DRAMATIC CHANGES IN HEPATIC REMETHYLATION REACTIONS AS THERE WAS A SIGNIFICANT DECREASE IN THE ENZYMES RESPONSIBLE FOR THE REGENERATION OF S-ADENOSYLMETHIONINE, AND, IN PARTICULAR, A SIGNIFICANT DECREASE IN THE BETAINE-HOMOCYSTEINE METHYLTRANSFERASE ENZYME. THIS SUGGESTED THAT HYPOMETHYLATION WAS ASSOCIATED WITH PROTEASOME INHIBITION, AS INDICATED BY THE DECREASE IN HISTONE METHYLATION. CONCLUSION: THE ROLE OF PROTEASOME INHIBITION IN REGULATING EPIGENETIC MECHANISMS, AND ITS LINK TO LIVER INJURY IN ALCOHOLIC LIVER DISEASE, IS THUS A PROMISING APPROACH TO STUDY LIVER INJURY DUE TO CHRONIC ETHANOL CONSUMPTION. 2009 7 3935 31 LIVER-SPECIFIC KNOCKDOWN OF CLASS IIA HDACS HAS LIMITED EFFICACY ON GLUCOSE METABOLISM BUT ENTAILS SEVERE ORGAN SIDE EFFECTS IN MICE. HISTONE DEACETYLASES (HDACS) ARE IMPORTANT REGULATORS OF EPIGENETIC GENE MODIFICATION THAT ARE INVOLVED IN THE TRANSCRIPTIONAL CONTROL OF METABOLISM. IN PARTICULAR CLASS IIA HDACS HAVE BEEN SHOWN TO AFFECT HEPATIC GLUCONEOGENESIS AND PREVIOUS APPROACHES REVEALED THAT THEIR INHIBITION REDUCES BLOOD GLUCOSE IN TYPE 2 DIABETIC MICE. IN THE PRESENT STUDY, WE AIMED TO EVALUATE THE POTENTIAL OF CLASS IIA HDAC INHIBITION AS A THERAPEUTIC OPPORTUNITY FOR THE TREATMENT +OF METABOLIC DISEASES. FOR THAT, SIRNAS SELECTIVELY TARGETING HDAC4, 5 AND 7 WERE SELECTED AND USED TO ACHIEVE A COMBINATORIAL KNOCKDOWN OF THESE THREE CLASS IIA HDAC ISOFORMS. SUBSEQUENTLY, THE HEPATOCELLULAR EFFECTS AS WELL AS THE IMPACT ON GLUCOSE AND LIPID METABOLISM WERE ANALYZED IN VITRO AND IN VIVO. THE TRIPLE KNOCKDOWN RESULTED IN A STATISTICALLY SIGNIFICANT DECREASE OF GLUCONEOGENIC GENE EXPRESSION IN MURINE AND HUMAN HEPATOCYTE CELL MODELS. A SIMILAR HDAC-INDUCED DOWNREGULATION OF HEPATIC GLUCONEOGENESIS GENES COULD BE ACHIEVED IN MICE USING A LIVER-SPECIFIC LIPID NANOPARTICLE SIRNA FORMULATION. HOWEVER, THE EFFICACY ON WHOLE BODY GLUCOSE METABOLISM ASSESSED BY PYRUVATE-TOLERANCE TESTS WERE ONLY LIMITED AND DID NOT OUTWEIGH THE SAFETY FINDINGS OBSERVED BY HISTOPATHOLOGICAL ANALYSIS IN SPLEEN AND KIDNEY. MECHANISTICALLY, AFFYMETRIX GENE EXPRESSION STUDIES PROVIDE EVIDENCE THAT CLASS IIA HDACS DIRECTLY TARGET OTHER KEY FACTORS BEYOND THE DESCRIBED FORKHEAD BOX (FOXP) TRANSCRIPTION REGULATORS, SUCH AS HEPATOCYTE NUCLEAR FACTOR 4 ALPHA (HNF4A). DOWNSTREAM OF THESE FACTORS SEVERAL ADDITIONAL PATHWAYS WERE REGULATED NOT MERELY INCLUDING GLUCOSE AND LIPID METABOLISM AND TRANSPORT. IN CONCLUSION, THE LIVER-DIRECTED COMBINATORIAL KNOCKDOWN OF HDAC4, 5 AND 7 BY THERAPEUTIC SIRNAS AFFECTED MULTIPLE PATHWAYS IN VITRO, LEADING IN VIVO TO THE DOWNREGULATION OF GENES INVOLVED IN GLUCONEOGENESIS. HOWEVER, THE EFFECTS ON GENE EXPRESSION LEVEL WERE NOT PARALLELED BY A SIGNIFICANT REDUCTION OF GLUCONEOGENESIS IN MICE. COMBINED KNOCKDOWN OF HDAC ISOFORMS WAS ASSOCIATED WITH SEVERE ADVERSE EFFECTS IN VIVO, CHALLENGING THIS APPROACH AS A TREATMENT OPTION FOR CHRONIC METABOLIC DISORDERS LIKE TYPE 2 DIABETES. 2020 8 3720 39 INHIBITION OF CLASS I HISTONE DEACETYLASES ABROGATES TUMOR GROWTH FACTOR BETA EXPRESSION AND DEVELOPMENT OF FIBROSIS DURING CHRONIC PANCREATITIS. PANCREATIC FIBROSIS IS THE HALLMARK OF CHRONIC PANCREATITIS, A HIGHLY DEBILITATING DISEASE FOR WHICH THERE IS CURRENTLY NO CURE. THE KEY EVENT AT THE BASIS OF PANCREATIC FIBROSIS IS THE DEPOSITION OF EXTRACELLULAR MATRIX PROTEINS BY ACTIVATED PANCREATIC STELLATE CELLS (PSCS). TRANSFORMING GROWTH FACTOR BETA (TGFBETA) IS A POTENT PROFIBROTIC FACTOR IN THE PANCREAS AS IT PROMOTES THE ACTIVATION OF PSC; THUS, PHARMACOLOGIC INTERVENTIONS THAT EFFECTIVELY REDUCE TGFBETA EXPRESSION HARBOR CONSIDERABLE THERAPEUTIC POTENTIAL IN THE TREATMENT OF CHRONIC PANCREATITIS. IN THIS STUDY, WE INVESTIGATED WHETHER TGFBETA EXPRESSION IS REDUCED BY PHARMACOLOGIC INHIBITION OF THE EPIGENETIC MODIFIERS HISTONE DEACETYLASES (HDACS). TO ADDRESS THIS AIM, CHRONIC PANCREATITIS WAS INDUCED IN C57BL/6 MICE WITH SERIAL INJECTIONS OF CERULEIN, AND THE SELECTIVE CLASS 1 HDAC INHIBITOR MS-275 WAS ADMINISTERED IN VIVO IN A PREVENTIVE AND THERAPEUTIC MANNER. BOTH MS-275 REGIMENS POTENTLY REDUCED DEPOSITION OF EXTRACELLULAR MATRIX AND DEVELOPMENT OF FIBROSIS IN THE PANCREAS AFTER 4 WEEKS OF CHRONIC PANCREATITIS. REDUCED PANCREATIC FIBROSIS WAS CONCOMITANT WITH LOWER EXPRESSION OF PANCREATIC TGFBETA AND CONSEQUENT REDUCED PSC ACTIVATION. IN SEARCH OF THE CELL TYPES TARGETED BY THE INHIBITOR, WE FOUND THAT MS-275 TREATMENT ABROGATED THE EXPRESSION OF TGFBETA IN ACINAR CELLS STIMULATED BY CERULEIN TREATMENT. OUR STUDY DEMONSTRATES THAT MS-275 IS AN EFFECTIVE ANTIFIBROTIC AGENT IN THE CONTEXT OF EXPERIMENTAL CHRONIC PANCREATITIS AND THUS MAY CONSTITUTE A VALID THERAPEUTIC INTERVENTION FOR THIS SEVERE DISEASE. 2018 9 476 45 ARSENIC INDUCES FIBROGENIC CHANGES IN HUMAN KIDNEY EPITHELIAL CELLS POTENTIALLY THROUGH EPIGENETIC ALTERATIONS IN DNA METHYLATION. ARSENIC CONTAMINATION IS A SIGNIFICANT PUBLIC HEALTH ISSUE, AND KIDNEY IS ONE OF THE TARGET ORGAN FOR ARSENIC-INDUCED ADVERSE EFFECTS. RENAL FIBROSIS IS A WELL-KNOWN PATHOLOGICAL STAGE FREQUENTLY OBSERVED IN PROGRESSIVE CHRONIC KIDNEY DISEASE (CKD). EPIDEMIOLOGICAL STUDIES IMPLICATE ARSENIC EXPOSURE TO CKD, BUT THE ROLE OF ARSENIC IN KIDNEY FIBROSIS AND THE UNDERLYING MECHANISM IS STILL UNCLEAR. IT IS IN THIS CONTEXT THAT THE CURRENT STUDY EVALUATED THE EFFECTS OF LONG-TERM ARSENIC EXPOSURE ON THE CELLULAR RESPONSE IN MORPHOLOGY, AND MARKER GENES EXPRESSION WITH RESPECT TO FIBROSIS USING HUMAN KIDNEY 2 (HK-2) EPITHELIAL CELLS. RESULTS OF THIS STUDY REVEALED THAT IN ADDITION TO INCREASED GROWTH, HK-2 CELLS UNDERWENT PHENOTYPIC, BIOCHEMICAL AND MOLECULAR CHANGES INDICATIVE OF EPITHELIAL-MESENCHYMAL TRANSITION (EMT) IN RESPONSE TO THE EXPOSURE TO ARSENIC. MOST IMPORTANTLY, THE ARSENIC-EXPOSED CELLS ACQUIRED THE PATHOGENIC FEATURES OF FIBROSIS AS SUPPORTED BY INCREASED EXPRESSION OF MARKERS FOR FIBROSIS, SUCH AS COLLAGEN I, FIBRONECTIN, TRANSFORMING GROWTH FACTOR BETA, AND ALPHA-SMOOTH MUSCLE ACTIN. UPREGULATION OF FIBROSIS ASSOCIATED SIGNALING MOLECULES SUCH AS TISSUE INHIBITOR OF METALLOPROTEINASES-3 AND MATRIX METALLOPROTEINASE-2 AS WELL AS ACTIVATION OF AKT WAS ALSO OBSERVED. ADDITIONALLY, THE EXPRESSION OF EPIGENETIC GENES (DNA METHYLTRANSFERASES 3A AND 3B; METHYL-CPG BINDING DOMAIN 4) WAS INCREASED IN ARSENIC-EXPOSED CELLS. TREATMENT WITH DNA METHYLATION INHIBITOR 5-AZA-2'-DC REVERSED THE EMT PROPERTIES AND RESTORED THE LEVEL OF PHOSPHO-AKT. TOGETHER, THESE DATA FOR THE FIRST TIME SUGGEST THAT LONG-TERM EXPOSURE TO ARSENIC CAN INCREASE THE RISK OF KIDNEY FIBROSIS. ADDITIONALLY, OUR DATA SUGGEST THAT THE ARSENIC-INDUCED FIBROTIC CHANGES ARE, AT LEAST IN PART, MEDIATED BY DNA METHYLATION AND THEREFORE POTENTIALLY CAN BE REVERSED BY EPIGENETIC THERAPEUTICS. 2019 10 4173 29 MELATONIN INDUCES HISTONE HYPERACETYLATION IN THE RAT BRAIN. WE HAVE REPORTED THAT MELATONIN INDUCES HISTONE HYPERACETYLATION IN MOUSE NEURAL STEM CELLS, SUGGESTING AN EPIGENETIC ROLE FOR THIS PLEIOTROPIC HORMONE. TO SUPPORT SUCH A ROLE, IT IS NECESSARY TO DEMONSTRATE THAT MELATONIN PRODUCES SIMILAR EFFECTS IN VIVO. HISTONE ACETYLATION, FOLLOWING CHRONIC TREATMENT WITH MELATONIN (4MUG/ML IN DRINKING WATER FOR 17 DAYS), WAS EXAMINED BY WESTERN BLOTTING IN SELECTED RAT BRAIN REGIONS. MELATONIN INDUCED SIGNIFICANT INCREASES IN HISTONE H3 AND HISTONE H4 ACETYLATION IN THE HIPPOCAMPUS. HISTONE H4 WAS ALSO HYPERACETYLATED IN THE STRIATUM, BUT THERE WERE NO SIGNIFICANT CHANGES IN HISTONE H3 ACETYLATION IN THIS BRAIN REGION. NO SIGNIFICANT CHANGES IN THE ACETYLATION OF EITHER HISTONE H3 OR H4 WERE OBSERVED IN THE MIDBRAIN AND CEREBELLUM. AN EXAMINATION OF KINASE ACTIVATION, WHICH MAY BE RELATED TO THESE CHANGES, REVEALED THAT MELATONIN TREATMENT INCREASED THE LEVELS OF PHOSPHO-ERK (EXTRACELLULAR SIGNAL-REGULATED KINASE) IN THE HIPPOCAMPUS AND STRIATUM, BUT PHOSPHO-AKT (PROTEIN KINASE B) LEVELS WERE UNCHANGED. THESE FINDINGS SUGGEST THAT CHROMATIN REMODELING AND ASSOCIATED CHANGES IN THE EPIGENETIC REGULATION OF GENE EXPRESSION UNDERLIE THE MULTIPLE PHYSIOLOGICAL EFFECTS OF MELATONIN. 2013 11 593 35 BET PROTEIN INHIBITION REGULATES CYTOKINE PRODUCTION AND PROMOTES NEUROPROTECTION AFTER SPINAL CORD INJURY. BACKGROUND: SPINAL CORD INJURY (SCI) USUALLY CAUSES A DEVASTATING LIFELONG DISABILITY FOR PATIENTS. AFTER A TRAUMATIC LESION, DISRUPTION OF THE BLOOD-SPINAL CORD BARRIER INDUCES THE INFILTRATION OF MACROPHAGES INTO THE LESION SITE AND THE ACTIVATION OF RESIDENT GLIAL CELLS, WHICH RELEASE CYTOKINES AND CHEMOKINES. THESE EVENTS RESULT IN A PERSISTENT INFLAMMATION, WHICH HAS BOTH DETRIMENTAL AND BENEFICIAL EFFECTS, BUT EVENTUALLY LIMITS FUNCTIONAL RECOVERY AND CONTRIBUTES TO THE APPEARANCE OF NEUROPATHIC PAIN. BROMODOMAIN AND EXTRA-TERMINAL DOMAIN (BET) PROTEINS ARE EPIGENETIC READERS THAT REGULATE THE EXPRESSION OF INFLAMMATORY GENES BY INTERACTING WITH ACETYLATED LYSINE RESIDUES. WHILE BET INHIBITORS ARE A PROMISING THERAPEUTIC STRATEGY FOR CANCER, LITTLE IS KNOWN ABOUT THEIR IMPLICATION AFTER SCI. THUS, THE CURRENT STUDY WAS AIMED TO INVESTIGATE THE ANTI-INFLAMMATORY ROLE OF BET INHIBITORS IN THIS PATHOLOGIC CONDITION. METHODS: WE EVALUATED THE EFFECTIVENESS OF THE BET INHIBITOR JQ1 TO MODIFY MACROPHAGE REACTIVITY IN VITRO AND TO MODULATE INFLAMMATION IN A SCI MICE MODEL. WE ANALYZED THE EFFECTS OF BET INHIBITION IN PRO-INFLAMMATORY AND ANTI-INFLAMMATORY CYTOKINE PRODUCTION IN VITRO AND IN VIVO. WE DETERMINED THE EFFECTIVENESS OF BET INHIBITION IN TISSUE SPARING, INFLAMMATION, NEURONAL PROTECTION, AND BEHAVIORAL OUTCOME AFTER SCI. RESULTS: WE HAVE FOUND THAT THE BET INHIBITOR JQ1 REDUCED THE LEVELS OF PRO-INFLAMMATORY MEDIATORS AND INCREASED THE EXPRESSION OF ANTI-INFLAMMATORY CYTOKINES. A PROLONGED TREATMENT WITH JQ1 ALSO DECREASED REACTIVITY OF MICROGLIA/MACROPHAGES, ENHANCED NEUROPROTECTION AND FUNCTIONAL RECOVERY, AND ACUTELY REDUCED NEUROPATHIC PAIN AFTER SCI. CONCLUSIONS: BET PROTEIN INHIBITION IS AN EFFECTIVE TREATMENT TO REGULATE CYTOKINE PRODUCTION AND PROMOTE NEUROPROTECTION AFTER SCI. THESE NOVEL RESULTS DEMONSTRATE FOR THE FIRST TIME THAT TARGETING BET PROTEINS IS AN ENCOURAGING APPROACH FOR SCI REPAIR AND A POTENTIAL STRATEGY TO TREAT OTHER INFLAMMATORY PATHOLOGIES. 2019 12 3240 32 HEPATIC LIPID ACCUMULATION ALTERS GLOBAL HISTONE H3 LYSINE 9 AND 4 TRIMETHYLATION IN THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA NETWORK. RECENT DATA SUGGEST THAT THE ETIOLOGY OF SEVERAL METABOLIC DISEASES IS CLOSELY ASSOCIATED WITH TRANSCRIPTOME ALTERATION BY ABERRANT HISTONE METHYLATION. WE PERFORMED DNA MICROARRAY AND CHIP-ON-CHIP ANALYSES TO EXAMINE TRANSCRIPTOME PROFILING AND TRIMETHYLATION ALTERATIONS TO IDENTIFY THE GENOMIC SIGNATURE OF NONALCOHOLIC FATTY LIVER DISEASE (NAFLD), THE MOST COMMON FORM OF CHRONIC LIVER DISEASE. TRANSCRIPTOME ANALYSIS SHOWED THAT STEATOTIC LIVERS IN HIGH-FAT DIET-FED APOLIPOPROTEIN E2 MICE SIGNIFICANTLY ALTERED THE EXPRESSION OF APPROXIMATELY 70% OF TOTAL GENES COMPARED WITH NORMAL DIET-FED CONTROL LIVERS, SUGGESTING THAT HEPATIC LIPID ACCUMULATION INDUCES DRAMATIC ALTERATIONS IN GENE EXPRESSION IN VIVO. ALSO, PATHWAY ANALYSIS SUGGESTED THAT GENES ENCODING CHROMATIN-REMODELING ENZYMES, SUCH AS JUMONJI C-DOMAIN-CONTAINING HISTONE DEMETHYLASES THAT REGULATE HISTONE H3K9 AND H3K4 TRIMETHYLATION (H3K9ME3, H3K4ME3), WERE SIGNIFICANTLY ALTERED IN STEATOTIC LIVERS. THUS, WE FURTHER INVESTIGATED THE GLOBAL H3K9ME3 AND H3K4ME3 STATUS IN LIPID-ACCUMULATED MOUSE PRIMARY HEPATOCYTES BY CHIP-ON-CHIP ANALYSIS. RESULTS SHOWED THAT HEPATIC LIPID ACCUMULATION INDUCED ABERRANT H3K9ME3 AND H3K4ME3 STATUS IN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AND HEPATIC LIPID CATABOLISM NETWORK GENES, REDUCING THEIR MRNA EXPRESSION COMPARED WITH NON-TREATED CONTROL HEPATOCYTES. THIS STUDY PROVIDES THE FIRST EVIDENCE THAT EPIGENETIC REGULATION BY H3K9ME3 AND H3K4ME3 IN HEPATOCYTES MAY BE INVOLVED IN HEPATIC STEATOSIS AND THE PATHOGENESIS OF NAFLD. THUS, CONTROL OF H3K9ME3 AND H3K4ME3 REPRESENTS A POTENTIAL NOVEL NAFLD PREVENTION AND TREATMENT STRATEGY. 2012 13 5860 32 SULFORAPHANE PREVENTS ANGIOTENSIN II-INDUCED CARDIOMYOPATHY BY ACTIVATION OF NRF2 THROUGH EPIGENETIC MODIFICATION. NUCLEAR FACTOR ERYTHROID 2-RELATED FACTOR (NRF2) IS AN IMPORTANT REGULATOR OF CELLULAR ANTIOXIDANT DEFENCE. WE PREVIOUSLY SHOWED THAT SFN PREVENTED ANG II-INDUCED CARDIAC DAMAGE VIA ACTIVATION OF NRF2. HOWEVER, THE UNDERLYING MECHANISM OF SFN'S PERSISTENT CARDIAC PROTECTION REMAINS UNCLEAR. THIS STUDY AIMED TO EXPLORE THE POTENTIAL OF SFN IN ACTIVATING CARDIAC NRF2 THROUGH EPIGENETIC MECHANISMS. WILD-TYPE MICE WERE INJECTED SUBCUTANEOUSLY WITH ANG II, WITH OR WITHOUT SFN. ADMINISTRATION OF CHRONIC ANG II-INDUCED CARDIAC INFLAMMATORY FACTOR EXPRESSION, OXIDATIVE DAMAGE, FIBROSIS AND CARDIAC REMODELLING AND DYSFUNCTION, ALL OF WHICH WERE EFFECTIVELY IMPROVED BY SFN TREATMENT, COUPLED WITH AN UP-REGULATION OF NRF2 AND DOWNSTREAM GENES. BISULFITE GENOME SEQUENCING AND CHROMATIN IMMUNOPRECIPITATION (CHIP) WERE PERFORMED TO DETECT THE METHYLATION LEVEL OF THE FIRST 15 CPGS AND HISTONE H3 ACETYLATION (AC-H3) STATUS IN THE NRF2 PROMOTER REGION, RESPECTIVELY. THE RESULTS SHOWED THAT SFN REDUCED ANG II-INDUCED CPG HYPERMETHYLATION AND PROMOTED AC-H3 ACCUMULATION IN THE NRF2 PROMOTER REGION, ACCOMPANIED BY THE INHIBITION OF GLOBAL DNMT AND HDAC ACTIVITY, AND A DECREASED PROTEIN EXPRESSION OF KEY DNMT AND HDAC ENZYMES. TAKEN TOGETHER, SFN EXERTS ITS CARDIOPROTECTIVE EFFECT THROUGH EPIGENETIC MODIFICATION OF NRF2, WHICH MAY PARTIALLY CONTRIBUTE TO LONG-TERM ACTIVATION OF CARDIAC NRF2. 2021 14 920 26 CHRONIC HYPOXIA FACILITATES ALZHEIMER'S DISEASE THROUGH DEMETHYLATION OF GAMMA-SECRETASE BY DOWNREGULATING DNA METHYLTRANSFERASE 3B. INTRODUCTION: ENVIRONMENTAL FACTORS AND EPIGENETIC MECHANISMS ARE BELIEVED TO CONTRIBUTE TO ALZHEIMER'S DISEASE (AD). WE PREVIOUSLY DOCUMENTED THAT PRENATAL HYPOXIA AGGRAVATED THE COGNITIVE IMPAIRMENT AND NEUROPATHOLOGY IN OFFSPRING MICE. HERE, WE INVESTIGATE THE CHRONIC HYPOXIA-INDUCED EPIGENETIC MODIFICATIONS IN AD. METHODS: THE 3-MONTH-OLD APP(SWE)/PS1(DE9) MICE WERE EXPOSED TO HYPOXIC ENVIRONMENT 6 HOUR/DAY FOR 30 DAYS, FOLLOWED BY LEARNING AND MEMORY TESTS AND BIOCHEMICAL AND NEUROPATHOLOGY MEASUREMENT AT THE AGE OF 4, 6, AND 9 MONTHS. RESULTS: WE FOUND HYPOXIA EXAGGERATED THE NEUROPATHOLOGY AND COGNITIVE IMPAIRMENT IN AD MICE. CHRONIC HYPOXIA INDUCED DEMETHYLATION ON GENOMIC DNA AND DECREASED THE EXPRESSION OF DNA METHYLTRANSFERASE 3B (DNMT3B) IN VIVO. WE FURTHER FOUND THAT DNMTS INHIBITION ELEVATED THE PROTEIN LEVELS OF AMYLOID PRECURSOR PROTEIN, BETA- AND GAMMA-SECRETASES, WHEREAS OVEREXPRESSION OF DNMT3B SUPPRESSED THE LEVELS OF THEM IN VITRO. DISCUSSION: OUR STUDY SUGGESTS CHRONIC HYPOXIA CAN AGGRAVATE AD PROGRESSION THROUGH DEMETHYLATION OF GENES ENCODING GAMMA-SECRETASE COMPONENTS BY DOWNREGULATION OF DNMT3B. 2016 15 1667 32 DOWNREGULATION OF PCAF BY MIR-181A/B PROVIDES FEEDBACK REGULATION TO TNF-ALPHA-INDUCED TRANSCRIPTION OF PROINFLAMMATORY GENES IN LIVER EPITHELIAL CELLS. ABERRANT CELLULAR RESPONSES TO PROINFLAMMATORY CYTOKINES, SUCH AS TNF-ALPHA, ARE PATHOGENIC FEATURES IN MOST CHRONIC INFLAMMATORY DISEASES. A VARIETY OF EXTRACELLULAR AND INTRACELLULAR FEEDBACK PATHWAYS HAS EVOLVED TO PREVENT AN INAPPROPRIATE CELLULAR REACTION TO THESE PROINFLAMMATORY CYTOKINES. IN THIS STUDY, WE REPORT THAT TNF-ALPHA TREATMENT OF HUMAN AND MOUSE CHOLANGIOCYTES AND HEPATOCYTES DOWNREGULATED EXPRESSION OF P300/CBP-ASSOCIATED FACTOR (PCAF), A COACTIVATOR AND AN ACETYLTRANSFERASE THAT PROMOTES HISTONE ACETYLATION AND GENE TRANSCRIPTION. OF THESE UPREGULATED MICRORNAS IN TNF-ALPHA-TREATED CELLS, MIR-181A/B (MIR-181A AND MIR-181B) SUPPRESSED TRANSLATION OF PCAF MRNA. FUNCTIONAL MANIPULATION OF MIR-181A/B CAUSED RECIPROCAL ALTERATIONS IN PCAF PROTEIN EXPRESSION IN CULTURED CHOLANGIOCYTES AND HEPATOCYTES. INHIBITION OF MIR-181A/B FUNCTION WITH ANTI-MIRS BLOCKED TNF-ALPHA-INDUCED SUPPRESSION OF PCAF EXPRESSION. PROMOTER RECRUITMENT OF PCAF WAS SHOWN TO BE ASSOCIATED WITH TNF-ALPHA-INDUCED TRANSCRIPTION OF INFLAMMATORY GENES. INTRIGUINGLY, PRETREATMENT OF CELLS WITH TNF-ALPHA INHIBITED TRANSCRIPTION OF INFLAMMATORY GENES IN RESPONSE TO SUBSEQUENT TNF-ALPHA STIMULATION. OVEREXPRESSION OF PCAF OR INHIBITION OF MIR-181A/B FUNCTION WITH ANTI-MIRS ATTENUATED THE INHIBITORY EFFECTS OF TNF-ALPHA PRETREATMENT ON EPITHELIAL INFLAMMATORY RESPONSE TO SUBSEQUENT TNF-ALPHA STIMULATION. DOWNREGULATION OF PCAF AND THE INHIBITORY EFFECTS OF TNF-ALPHA PRETREATMENT ON LIVER EPITHELIAL INFLAMMATORY RESPONSE WERE FURTHER CONFIRMED IN A MOUSE MODEL OF TNF-ALPHA I.P. INJECTION. THESE DATA SUGGEST THAT PCAF IS A TARGET FOR MIR-181A/B, AND DOWNREGULATION OF PCAF BY TNF-ALPHA PROVIDES NEGATIVE FEEDBACK REGULATION TO INFLAMMATORY REACTIONS IN LIVER EPITHELIAL CELLS, A PROCESS THAT MAY BE RELEVANT TO THE EPIGENETIC FINE-TUNING OF EPITHELIAL INFLAMMATORY PROCESSES IN GENERAL. 2012 16 793 37 CELLULAR RE- AND DE-PROGRAMMING BY MICROENVIRONMENTAL MEMORY: WHY SHORT TGF-BETA1 PULSES CAN HAVE LONG EFFECTS. BACKGROUND: FIBROSIS POSES A SUBSTANTIAL SETBACK IN REGENERATIVE MEDICINE. HISTOPATHOLOGICALLY, FIBROSIS IS AN EXCESSIVE ACCUMULATION OF COLLAGEN AFFECTED BY MYOFIBROBLASTS AND THIS CAN OCCUR IN ANY TISSUE THAT IS EXPOSED TO CHRONIC INJURY OR INSULT. TRANSFORMING GROWTH FACTOR (TGF)-BETA1, A CRUCIAL MEDIATOR OF FIBROSIS, DRIVES DIFFERENTIATION OF FIBROBLASTS INTO MYOFIBROBLASTS. THESE CELLS EXHIBIT ALPHA-SMOOTH MUSCLE ACTIN (ALPHA-SMA) AND SYNTHESIZE HIGH AMOUNTS OF COLLAGEN I, THE MAJOR EXTRACELLULAR MATRIX (ECM) COMPONENT OF FIBROSIS. WHILE HORMONES STIMULATE CELLS IN A PULSATILE MANNER, LITTLE IS KNOWN ABOUT CELLULAR RESPONSE KINETICS UPON GROWTH FACTOR IMPACT. WE THEREFORE STUDIED THE EFFECTS OF SHORT TGF-BETA1 PULSES IN TERMS OF THE INDUCTION AND MAINTENANCE OF THE MYOFIBROBLAST PHENOTYPE. RESULTS: TWENTY-FOUR HOURS AFTER A SINGLE 30 MIN TGF-BETA1 PULSE, TRANSCRIPTION OF FIBROGENIC GENES WAS UPREGULATED, BUT SUBSIDED 7 DAYS LATER. IN PARALLEL, COLLAGEN I SECRETION RATE AND ALPHA-SMA PRESENCE WERE ELEVATED FOR 7 DAYS. A SECOND PULSE 24 H LATER EXTENDED THE DURATION OF EFFECTS TO 14 DAYS. WE COULD NOT ESTABLISH EPIGENETIC CHANGES ON FIBROGENIC TARGET GENES TO EXPLAIN THE LONG-LASTING EFFECTS. HOWEVER, ECM DEPOSITED UNDER SINGLY PULSED TGF-BETA1 WAS ABLE TO INDUCE MYOFIBROBLAST FEATURES IN PREVIOUSLY UNTREATED FIBROBLASTS. DEPENDENT ON THE AGE OF THE ECM (1 DAY VERSUS 7 DAYS' FORMATION TIME), THIS PROPERTY WAS DIMINISHED. VICE VERSA, MYOFIBROBLASTS WERE CULTURED ON FIBROBLAST ECM AND CELLS OBSERVED TO EXPRESS REDUCED (IN COMPARISON WITH MYOFIBROBLASTS) LEVELS OF COLLAGEN I. CONCLUSIONS: WE DEMONSTRATED THAT SHORT TGF-BETA1 PULSES CAN EXERT LONG-LASTING EFFECTS ON FIBROBLASTS BY CHANGING THEIR MICROENVIRONMENT, THUS LEAVING AN IMPRINT AND CREATING A RECIPROCAL FEED-BACK LOOP. THEREFORE, THE ECM MIGHT ACT AS MID-TERM MEMORY FOR PATHOBIOCHEMICAL EVENTS. WE WOULD EXPECT THIS MICROENVIRONMENTAL MEMORY TO BE DEPENDENT ON MATRIX TURNOVER AND, AS SUCH, TO BE ERASABLE. OUR FINDINGS CONTRIBUTE TO THE CURRENT UNDERSTANDING OF FIBROBLAST INDUCTION AND MAINTENANCE, AND HAVE BEARING ON THE DEVELOPMENT OF ANTIFIBROTIC DRUGS. 2013 17 1906 39 ENHANCER OF ZESTE HOMOLOG 2-CATALYSED H3K27 TRIMETHYLATION PLAYS A KEY ROLE IN ACUTE-ON-CHRONIC LIVER FAILURE VIA TNF-MEDIATED PATHWAY. ACUTE-ON-CHRONIC LIVER FAILURE IS MAINLY DUE TO HOST IMMUNITY SELF-DESTRUCTION. THE HISTONE H3 LYSINE 27 (H3K27) TRIMETHYLATING ENZYME, ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MEDIATES EPIGENETIC SILENCING OF GENE EXPRESSION AND REGULATES IMMUNITY, ALSO INVOLVES PATHOGENESIS OF SEVERAL LIVER DISEASES. THE CURRENT STUDY WAS TO DETERMINE THE ROLE OF METHYLTRANSFERASE EZH2 AND ITS CATALYSED H3K27 TRIMETHYLATION (H3K27ME3) IN LIVER FAILURE, AND TO FURTHER INVESTIGATE THE POTENTIAL TARGET FOR LIVER FAILURE TREATMENT. EZH2 AND ITS CATALYSED H3K27ME3 WERE DETERMINED IN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC) FROM LIVER FAILURE PATIENTS AND KUPFFER CELLS FROM EXPERIMENTAL MICE. FURTHERMORE, GSK126 (AN INHIBITOR FOR EZH2 TRIMETHYLATION FUNCTION) WAS APPLIED IN LIVER FAILURE MICE IN VIVO, AND LIPOPOLYSACCHARIDE-STIMULATED MONONUCLEAR CELLS IN VITRO. EZH2 AND H3K27ME3 WERE SIGNIFICANTLY UPREGULATED IN HUMAN PBMC FROM LIVER FAILURE PATIENTS OR MURINE KUPFFER CELLS FROM THE LIVER FAILURE ANIMALS, RESPECTIVELY. GSK126 AMELIORATED DISEASE SEVERITY IN LIVER FAILURE MICE, WHICH MAYBE ATTRIBUTE TO DOWN-REGULATE CIRCULATING AND HEPATIC PROINFLAMMATORY CYTOKINES, ESPECIALLY TNF VIA REDUCING H3K27ME3. IN-DEPTH CHROMATIN IMMUNOPRECIPITATION ANALYSIS UNRAVELLED THAT DECREASED ENRICHMENT OF H3K27ME3 ON TNF PROMOTOR, RESULTING IN TNF ELEVATION IN KUPFFER CELLS FROM LIVER FAILURE MICE. NUCLEAR FACTOR KAPPA B (NF-KAPPAB) AND PROTEIN KINASE B (AKT) SIGNALLING PATHWAYS WERE ACTIVATED UPON LIPOPOLYSACCHARIDE STIMULATION, BUT ATTENUATED BY USING GSK126, ACCOMPANIED WITH DECREASED TNF IN VITRO. IN CONCLUSION, EZH2 AND H3K27ME3 CONTRIBUTED TO THE PATHOGENESIS OF LIVER FAILURE VIA TRIGGERING TNF AND OTHER INDISPENSABLE PROINFLAMMATORY CYTOKINES. EZH2 WAS TO MODIFY H3K27ME3 ENRICHMENT, AS WELL AS, ACTIVATION OF THE DOWNSTREAM NF-KAPPAB AND AKT SIGNALLING PATHWAYS. 2018 18 5074 26 PHYSIOLOGIC AND EPIGENETIC EFFECTS OF NUTRIENTS ON DISEASE PATHWAYS. BACKGROUND/OBJECTIVES: EPIGENETIC REGULATION BY NUTRIENTS CAN INFLUENCE THE DEVELOPMENT OF SPECIFIC DISEASES. THIS STUDY SOUGHT TO EXAMINE THE EFFECT OF INDIVIDUAL NUTRIENTS AND NUTRIENT FAMILIES IN THE CONTEXT OF PREVENTING CHRONIC METABOLIC DISEASES VIA EPIGENETIC REGULATION. THE INHIBITION OF LIPID ACCUMULATION AND INFLAMMATION BY NUTRIENTS INCLUDING PROTEINS, LIPIDS, VITAMINS, AND MINERALS WERE OBSERVED, AND HISTONE ACETYLATION BY HISTONE ACETYLTRANSFERASE (HAT) WAS MEASURED. CORRELATIVE ANALYSES WERE ALSO PERFORMED. MATERIALS/METHODS: NUTRIENTS WERE SELECTED ACCORDING TO INFORMATION FROM THE KOREAN MINISTRY OF FOOD AND DRUG SAFETY. SELECTED NUTRIENT FUNCTIONALITIES, INCLUDING THE ATTENUATION OF FATTY ACID-INDUCED LIPID ACCUMULATION AND LIPOPOLYSACCHARIDE-MEDIATED ACUTE INFLAMMATION WERE EVALUATED IN MOUSE MACROPHAGE RAW264.7 AND MOUSE HEPATOCYTE AML-12 CELLS. EFFECTS OF THE SELECTED NUTRIENTS ON IN VITRO HAT INHIBITION WERE ALSO EVALUATED. RESULTS: NITRIC OXIDE (NO) PRODUCTION CORRELATED WITH HAT ACTIVITY, WHICH WAS REGULATED BY THE AMINO ACIDS GROUP, SUGGESTING THAT AMINO ACIDS POTENTIALLY CONTRIBUTE TO THE ATTENUATION OF NO PRODUCTION VIA THE INHIBITION OF HAT ACTIVITY. UNSATURATED FATTY ACIDS TENDED TO ATTENUATE INFLAMMATION BY INHIBITING NO PRODUCTION, WHICH MAY BE ATTRIBUTABLE TO THE INHIBITION OF IN VITRO HAT ACTIVITY. IN CONTRAST TO WATER-SOLUBLE VITAMINS, THE LIPID-SOLUBLE VITAMINS SIGNIFICANTLY DECREASED NO PRODUCTION. WATER- AND LIPID-SOLUBLE VITAMINS BOTH EXHIBITED SIGNIFICANT INHIBITORY ACTIVITIES AGAINST HAT. IN ADDITION, CALCIUM AND MANGANESE SIGNIFICANTLY INHIBITED LIPID ACCUMULATION, NO PRODUCTION, AND HAT ACTIVITY. CONCLUSIONS: SEVERAL CANDIDATE NUTRIENTS AND THEIR FAMILY MEMBERS MAY HAVE ROLES IN THE PREVENTION OF DISEASES, INCLUDING HEPATIC STEATOSIS AND INFLAMMATION-RELATED DISEASES (I.E., NONALCOHOLIC STEATOHEPATITIS) VIA EPIGENETIC REGULATION. FURTHER STUDIES ARE WARRANTED TO DETERMINE WHICH SPECIFIC AMINO ACIDS, UNSATURATED FATTY ACIDS AND LIPID-SOLUBLE VITAMINS OR SPECIFIC MINERALS INFLUENCE THE DEVELOPMENT OF STEATOSIS AND INFLAMMATORY-RELATED DISEASES. 2023 19 3341 25 HISTONE DEACETYLASE-2 IS INVOLVED IN STRESS-INDUCED COGNITIVE IMPAIRMENT VIA HISTONE DEACETYLATION AND PI3K/AKT SIGNALING PATHWAY MODIFICATION. EXPOSURE TO CHRONIC STRESS UPREGULATES BLOOD GLUCOCORTICOID LEVELS AND IMPAIRS COGNITION VIA DIVERSE EPIGENETIC MECHANISMS, SUCH AS HISTONE DEACETYLATION. HISTONE DEACETYLATION CAN LEAD TO TRANSCRIPTIONAL SILENCING OF MANY PROTEINS INVOLVED IN COGNITION AND MAY ALSO CAUSE LEARNING AND MEMORY DYSFUNCTION. HISTONE DEACETYLASE?2 (HDAC2) HAS BEEN DEMONSTRATED TO EPIGENETICALLY BLOCK COGNITION VIA A REDUCTION IN THE HISTONE ACETYLATION LEVEL; HOWEVER, IT IS UNKNOWN WHETHER HDAC2 IS INVOLVED IN THE COGNITIVE DECLINE INDUCED BY CHRONIC STRESS. TO THE BEST OF AUTHORS' KNOWLEDGE, THIS IS THE FIRST STUDY TO DEMONSTRATE THAT THE STRESS HORMONE CORTICOSTEROID UPREGULATE HDAC2 PROTEIN LEVELS IN NEURO?2A CELLS AND CAUSE CELL INJURIES. HDAC2 KNOCKDOWN RESULTED IN A SIGNIFICANT AMELIORATION OF THE PATHOLOGICAL CHANGES IN N2A CELLS VIA THE UPREGULATION OF HISTONE ACETYLATION AND MODIFICATIONS IN THE PHOSPHOINOSITIDE 3?KINASE/PROTEIN KINASE B SIGNALING PATHWAY. IN ADDITION, THE HDAC2 PROTEIN LEVELS WERE UPREGULATED IN 12?MONTH?OLD FEMALE C57BL/6J MICE UNDER CHRONIC STRESS IN VIVO. TAKEN TOGETHER, THESE FINDINGS SUGGESTED THAT HDAC2 MAY BE AN IMPORTANT NEGATIVE REGULATOR INVOLVED IN CHRONIC STRESS?INDUCED COGNITIVE IMPAIRMENT. 2017 20 1826 38 EFFECTS OF HISTONE DEACETYLASE INHIBITOR ON EXTRACELLULAR MATRIX PRODUCTION IN HUMAN NASAL POLYP ORGAN CULTURES. BACKGROUND: NASAL POLYPOSIS IS ASSOCIATED WITH A CHRONIC INFLAMMATORY CONDITION OF THE SINONASAL MUCOSA AND INVOLVES MYOFIBROBLAST DIFFERENTIATION AND EXTRACELLULAR MATRIX (ECM) ACCUMULATION. EPIGENETIC MODULATION BY HISTONE DEACETYLASE (HDAC) INHIBITORS INCLUDING TRICHOSTATIN A (TSA) HAS BEEN REPORTED TO HAVE INHIBITORY EFFECTS ON MYOFIBROBLAST DIFFERENTIATION IN LUNG AND RENAL FIBROBLASTS. THE PURPOSE OF THIS STUDY WAS TO INVESTIGATE THE INHIBITORY EFFECT OF TSA ON MYOFIBROBLAST DIFFERENTIATION AND ECM PRODUCTION IN NASAL POLYP ORGAN CULTURES. METHODS: NASAL POLYP TISSUES FROM 18 PATIENTS WERE ACQUIRED DURING ENDOSCOPIC SINUS SURGERY. AFTER ORGAN CULTURE, NASAL POLYPS WERE STIMULATED WITH TGF-BETA1 AND THEN TREATED WITH TSA. ALPHA-SMOOTH MUSCLE ACTIN (ALPHA-SMA), FIBRONECTIN, AND COLLAGEN TYPE I EXPRESSION LEVELS WERE EXAMINED BY REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION (PCR), REAL-TIME PCR, WESTERN BLOT, AND IMMUNOFLUORESCENT STAINING. HDAC2, HDAC4, AND ACETYLATED H4 EXPRESSION LEVELS WERE ASSAYED BY WESTERN BLOT. CYTOTOXICITY WAS ANALYZED BY THE TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE BIOTIN-DUTP NICK END LABELING ASSAY. RESULTS: THE EXPRESSION LEVELS OF ALPHA-SMA, FIBRONECTIN, AND COLLAGEN TYPE 1 WERE INCREASED IN NASAL POLYP AFTER TRANSFORMING GROWTH FACTOR (TGF) BETA1 TREATMENT. TSA-INHIBITED TGF-BETA1 INDUCED THESE GENE AND PROTEIN EXPRESSION LEVELS. FURTHERMORE, TSA SUPPRESSED PROTEIN EXPRESSION LEVELS OF HDAC2 AND HDAC4. HOWEVER, TSA INDUCED HYPERACETYLATION OF HISTONES H4. TREATMENT WITH TGF-BETA1 WITH OR WITHOUT TSA DID NOT HAVE CYTOTOXIC EFFECT. CONCLUSION: THESE FINDINGS PROVIDE NOVEL INSIGHTS INTO THE EPIGENETIC REGULATION IN MYOFIBROBLAST DIFFERENTIATION AND ECM PRODUCTION OF NASAL POLYP. TSA COULD BE A CANDIDATE OF A THERAPEUTIC AGENT FOR REVERSING THE TGF-BETA1-INDUCED ECM SYNTHESIS THAT LEADS TO NASAL POLYP DEVELOPMENT. 2013